Cyclerion Therapeutics, Inc. (CYCN)
23.52
-6.23 (-20.94%)
Inactive · Last trade price on Sep 8, 2026
Cyclerion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.9 | 2.07 | 2 | - | 0.3 | 3.94 | |
Revenue Growth | -12.60% | 3.70% | - | - | -92.47% | 71.69% |
Cost of Revenue | 1.6 | 0.96 | 0.29 | 1.32 | 5.58 | 37.64 |
Gross Profit | 0.3 | 1.12 | 1.71 | -1.32 | -5.28 | -33.69 |
Selling, General & Admin | 7.13 | 6.09 | 5.34 | 8.33 | 13.26 | 20.62 |
Operating Expenses | 7.13 | 6.09 | 5.34 | 8.33 | 13.26 | 20.62 |
Operating Income | -6.82 | -4.97 | -3.63 | -9.65 | -18.54 | -54.31 |
Interest Expense | - | - | - | - | - | -0.02 |
Interest & Investment Income | 0.12 | 0.13 | 0.21 | 0.36 | 0.29 | - |
Other Non Operating Income (Expenses) | - | - | 0.36 | - | - | - |
EBT Excluding Unusual Items | -6.71 | -4.85 | -3.06 | -9.29 | -18.25 | -54.33 |
Asset Writedown | - | - | - | -3.3 | - | - |
Other Unusual Items | - | - | - | - | - | 2.68 |
Pretax Income | -6.71 | -3.53 | -3.06 | -12.59 | -18.25 | -51.65 |
Earnings From Continuing Operations | -6.71 | -3.53 | -3.06 | -12.59 | -18.25 | -51.65 |
Earnings From Discontinued Operations | - | - | - | 7.33 | -25.83 | - |
Net Income | -6.71 | -3.53 | -3.06 | -5.26 | -44.08 | -51.65 |
Net Income to Common | -6.71 | -3.53 | -3.06 | -5.26 | -44.08 | -51.65 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 3 | 3 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 4 | 3 | 3 | 2 | 2 | 2 |
Shares Change | 44.12% | 26.33% | 7.70% | 7.59% | 11.03% | 28.75% |
EPS (Basic) | -1.73 | -1.11 | -1.21 | -2.25 | -20.28 | -26.39 |
EPS (Diluted) | -1.73 | -1.11 | -1.21 | -2.25 | -20.28 | -26.39 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4.52 | -3.31 | -4.33 | -21.25 | -40.61 | -36.52 |
Free Cash Flow Per Share | -1.17 | -1.04 | -1.72 | -9.09 | -18.69 | -18.66 |
Gross Margin | 15.95% | 53.76% | 85.70% | - | - | - |
Operating Margin | -359.16% | -239.78% | -181.40% | - | -6242.42% | -1377.83% |
Profit Margin | -353.00% | -170.11% | -152.85% | - | -14841.08% | -1310.17% |
Free Cash Flow Margin | -237.74% | -159.79% | -216.65% | - | -13673.74% | -926.53% |
EBITDA | - | - | - | -9.58 | -18.48 | -53.84 |
D&A For EBITDA | - | - | - | 0.07 | 0.07 | 0.47 |
EBIT | -6.82 | -4.97 | -3.63 | -9.65 | -18.54 | -54.31 |
EBIT Margin | - | -239.78% | -181.40% | - | - | - |
Revenue as Reported | 1.9 | 2.07 | 2 | - | 0.3 | 3.94 |